Johnson & Johnson Collaborates with the Beth Israel Deaconess Medical Center to Accelerate the Development of Vaccine Against COVID-19

 Johnson & Johnson Collaborates with the Beth Israel Deaconess Medical Center to Accelerate the Development of Vaccine Against COVID-19

Johnson & Johnson Collaborates with the Beth Israel Deaconess Medical Center to Accelerate the Development of Vaccine Against COVID-19

Shots:

  • The collaboration leads to the starting of pre-clinical testing of multiple vaccine prospects, intending to identify the vaccine candidate for clinical studies, by the month-end
  • Janssen will utilize its AdVac and PER.C6 technologies (technologies that were used to develop Ebola, Zika, RSV, & HIV vaccine) for rapidly upscale production of an optimal vaccine candidate. J&J is expected to initiate the P-I clinical study by the end of the year
  • J&J is in collaboration with global strategic partners to screen its antiviral molecules’ library for accelerating the discovery of COVID-19 treatments

Click here ­to­ read full press release/ article | Ref: J&J | Image: The Pharma Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post